The 64 th storefront in Florida offers the largest inventory of medical cannabis products in the state

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 66th nationwide. The new dispensary will be the first location in Punta Gorda and third in Charlotte County to bring the Company’s wide-ranging catalog of medical cannabis products directly to patients.


Located on Tamiami Trail, the new dispensary supports Trulieve’s goal of expanding and ensuring direct, reliable patient access to medical cannabis across its home state of Florida . It joins the Company’s 63 other dispensaries statewide, including those in nearby Port Charlotte , Englewood , and Fort Myers .

“We believe patients should be able to safely and consistently have access to the medications they rely on and use daily, which means opening stores in locations that best benefit patients, like Punta Gorda ,” said Trulieve CEO Kim Rivers . “Each location is about more than just access; each store allows us to genuinely connect with the community. As the first medical cannabis company in Punta Gorda , we understand people may have questions about Florida’s medical cannabis program; we encourage those interested in learning more to visit our website and connect with our highly-educated team to get information on the program, our company, and any questions they may have.”

In honor of the Company’s brand new dispensary, all patients — from those new to Trulieve to the dedicated Truliever community — will be eligible for a 25% in-store discount at the new Punta Gorda dispensary on opening day. In line with policies adopted statewide, all visitors are required to wear masks inside the dispensary. Additionally, only patients and their state-approved caregivers will be allowed inside the waiting room and dispensary at this time.

ANNOUNCING : Trulieve Punta Gorda Opening
WHERE : 10175 Tamiami Trail, Suite 1105, Punta Gorda, Florida 33950
WHEN : Wednesday, October 28, 2020 , at 9:00 AM

In stores and online, patients will find Florida’s largest selection of THC and CBD products , available in a variety of delivery methods, including edibles, smokable cannabis, concentrates, tinctures, topical creams, vaporizers, and more. Trulieve also offers home delivery statewide for patients and convenient in-store pickup at each of its 64 dispensaries in the state.

To assist patients with ordering, Trulieve has made our entire catalog of products available for online ordering, with in-store pickup, curbside pickup (at select locations), or statewide home delivery options available. In addition, patients can schedule a 30-minute complimentary virtual consultation with a Trulieve certified consultant to help navigate questions on products, devices or to review their doctor’s recommendation. To learn more about consultations, click here to read Trulieve’s blog .

Furthermore, to assist with CDC recommendations for social distancing and in compliance with additional company-enforced safety guidelines, several measures have been taken to ensure the health and well-being of employees and patients, including modifying the store layout, installation of plexiglass partitions and HEPA air filtration scrubbers in the dispensaries, increasing access to masks and sanitizer throughout the store for staff and visitors, utilizing visual aids to direct traffic throughout the store, and increasing the frequency of deep cleanings for all dispensaries.

Trulieve is closely monitoring the coronavirus situation and will update store policies as needed to ensure the safety of patients and staff; all updates will be shared directly on Trulieve’s website as they are enacted.

The Office of Medical Marijuana Use recently announced the registry was approaching 440,000 registered medical marijuana patients with an active ID card, with Trulieve consistently selling approximately half of the state’s overall volume per the Florida Department of Health. To support the state’s rapidly growing patient base, there are nearly 2,700 registered ordering physicians in the State of Florida .

For more information, please visit www.Trulieve.com .

About Trulieve
Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida . Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida , as well as directly to patients via home delivery. Trulieve also operates in California , Massachusetts , and Connecticut . Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.

To learn more about Trulieve, visit www.Trulieve.com .

Cision View original content: http://www.prnewswire.com/news-releases/trulieve-opens-punta-gordas-first-dispensary-brings-access-directly-to-patients-301160816.html

SOURCE Trulieve Cannabis Corp.

News Provided by Canada Newswire via QuoteMedia

 Sweet Earth Holdings Corp. (CSE: SE) (FSE: 1KZ1) (OTCQB: SEHCF) (“Sweet Earth” the “Company”) is pleased to announce that it has received full Depository Trust Company (“DTC”) eligibility in the United States. On October 20, 2020, Sweet Earth announced that its shares had been listed on the United States’ Over-The-Counter Bulletin (“OTCQB”) under the ticker SEHCF.

DTC status means that Sweet Earth shares are now eligible to be transferred between brokerage accounts within the United States and significantly augments the ease in which American-based investors are able to trade Sweet Earth shares.

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”), announces that further to its press releases dated July 21, 2020 and July 31, 2020, the Company proposes to amend the exercise price of 19,405,804 warrants of the Company that were originally issued on July 27, 2018, to $0.10. These warrants are set to expire on December 31, 2020.

The Company had initially proposed a lower amended price, but that proposal was not approved by the TSX Venture Exchange (“Exchange“), however, the Exchange indicated that a $0.10 exercise price, may be more acceptable. Accordingly, the proposed amendment remains subject to Exchange approval.

Keep reading... Show less

Issuance of U.S. Patent No. 10,851,077 covering methods for extracting and concentrating cannabinoids using ultrasound-enhanced solvent extraction bolsters World Class’ intellectual patent portfolio

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announced the United States Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 10,851,077 on December 1, 2020 in relation to the Company’s methods for extracting and concentrating cannabinoids and other target compounds from cannabis using ultrasound-enhanced solvent extraction

Keep reading... Show less

Ubican brings well-known brands and is a trusted vendor with an established sales and marketing program

Chemesis International Inc. (CSE:CSI) (OTCQB:CADMF) (FRA:CWAA) (the “Company” or “Chemesis”), announces Ubican Global (“Ubican”) as its primary supplier for its United States VICKI program. Ubican is a trusted supplier of a family of brands, each with multiple types of products. The products include tinctures, digestibles, edibles, pet, beautyskincare, topical, edible, fitness, and smokable products

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce that it has engaged VisionWorks Engineering of San Diego, CA to commence engineering work to complete and test a proof of concept prototype of its nasal mist device.

This is a major milestone towards the ultimate goal for development of effective delivery methods and commercialization. The Company holds several provisional patent applications including for a nasal mist device entitled “Device and Method for the Treatment of Traumatic Brain Injuries and Post-Traumatic Stress Disorder”. This device includes a nasal delivery system for administration of pharmaceutical agents such as a psilocybin-derived agent and/or N-acetylcysteine (“NAC“) at preselected dosages and times. The device design allows for the precise control and delivery of medicines through the nasal cavity for faster and more efficient uptake of psychedelics and other medicines that target the brain.

Keep reading... Show less